Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer Journal Article
| Authors: | Riedl, C. C.; Pinker, K.; Ulaner, G. A.; Ong, L. T.; Baltzer, P.; Jochelson, M. S.; McArthur, H. L.; Gönen, M.; Dickler, M.; Weber, W. A. |
| Article Title: | Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer |
| Abstract: | Purpose: The aim of this study was to compare fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) and contrast-enhanced computed tomography (CE-CT) for the prediction of progression-free survival (PFS) and disease-specific survival (DSS) in patients with stage IV breast cancer undergoing systemic therapy. Methods: Sixty-five patients with metastatic breast cancer treated with first- or second-line systemic therapy in prospective clinical trials were included. Response to treatment was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for CE-CT and by PET Response Criteria in Solid Tumors (PERCIST), respectively. Results: All responders by RECIST (n = 22) were also responders by PERCIST, but 40% (17/43) of non-responders by RECIST were responders by PERCIST. Responses according to RECIST and PERCIST both correlated with PFS, but PERCIST showed a significantly higher predictive accuracy (concordance index for PFS: 0.70 vs. 0.60). One-year PFS for responders vs. non-responders by RECIST was 59% vs. 27%, compared to 63% vs. 0% by PERCIST. Four-year DSS of responders and non-responders by RECIST was 50% and 38%, respectively (p = 0.2, concordance index: 0.55) as compared to 58% vs. 18% for PERCIST (p < 0.001, concordance index: 0.65). Response on PET/CT was also a significantly better predictor for DSS than disease control on CE-CT. Conclusions: In patients with metastatic breast cancer, tumor response on PET/CT appears to be a superior predictor of PFS and DSS than response on CE-CT. Monitoring tumor response by PET/CT may increase the power of clinical trials using tumor response as an endpoint, and may improve patient management in clinical routine. © 2017, Springer-Verlag Berlin Heidelberg. |
| Keywords: | survival; treatment response; breast cancer; fdg; pet/ct |
| Journal Title: | European Journal of Nuclear Medicine and Molecular Imaging |
| Volume: | 44 |
| Issue: | 9 |
| ISSN: | 1619-7070 |
| Publisher: | Springer |
| Date Published: | 2017-08-01 |
| Start Page: | 1428 |
| End Page: | 1437 |
| Language: | English |
| DOI: | 10.1007/s00259-017-3703-7 |
| PROVIDER: | scopus |
| PMCID: | PMC5526620 |
| PUBMED: | 28462446 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 August 2017 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work